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Abstract
Objective Cognitive-driven activity of daily living (ADL) impairment in Parkinson’s disease (PD) is increasingly discussed 
as prodromal marker for dementia. Diagnostic properties of assessments for this specific ADL impairment are sparsely 
investigated in PD. The ability of the Functional Activities Questionnaire (FAQ) for differentiating between PD patients with 
normal cognition and with mild cognitive impairment (PD-MCI), according to informant and self-reports, was examined. 
Global cognitive function in groups with and without mild ADL impairment was compared according to different cut-offs.
Methods Multicenter data of 589 patients of an international cohort (CENTRE-PD) were analyzed. Analyses were run sepa-
rately for informant-rated and self-rated FAQ. Receiver operating characteristic (ROC) analysis was conducted to define the 
optimal FAQ cut-off for PD-MCI (≥ 1), and groups were additionally split according to reported FAQ cut-offs for PD-MCI 
in the literature (≥ 3, ≥ 5). Binary logistic regressions examined the effect of the Montreal Cognitive Assessment (MoCA) 
score in PD patients with and without mild ADL impairment.
Results Two hundred and twenty-five (38.2%) patients were classified as PD-MCI. For all three cut-off values, sensitivity 
was moderate to low (< 0.55), but specificity was moderately high (> 0.54) with a tendency of higher values for self-reported 
deficits. For the self-report, the cut-off ≥ 3 showed a significant effect of the MoCA (B =  − 0.31, p = 0.003), where FAQ ≥ 3 
patients had worse cognition. No effect for group differences based on informant ratings was detected.
Conclusion Our data argue that self-reported ADL impairments assessed by the FAQ show a relation to the severity of 
cognitive impairment in PD.
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Mild cognitive impairment (MCI) in Parkinson’s disease 
(PD-MCI) has been defined as a prodromal stage of Par-
kinson’s disease (PD) dementia (PDD) [1]. While PD-MCI 
patients are at greater risk of developing PDD [2], it is not 
possible to predict which patients convert within a short 
time period. Additional markers indicating patients at risk 
for PDD conversion are therefore urgently needed.
In non-PD cohorts, instrumental activity of daily liv-
ing (ADL) impairments have been reported to emerge in 
the transition from MCI to dementia, affecting complex 
skills such as managing finances [3, 4]. Impairments in 
these functional abilities are even strong predictors of 
future conversion to dementia [5]. In PD, research demon-
strates that non-demented patients already show functional 
impairment [6, 7], primarily related to loss of cognitive 
function [8, 9]. Mild ADL impairment in PD-MCI patients 
might help to identify those at risk for PDD conversion [7, 
8], necessitating an early diagnosis of ADL impairment in 
the prodromal stage of PDD using sensitive and reliable 
measures.
One of the most commonly used scales to measure ADL 
impairment is the Pfeffer Functional Activities Question-
naire (FAQ) [10], which has a high discriminative ability 
for distinguishing MCI from other diagnostic groups [11]. 
For non-PD cohorts, a cut-off score of ≥ 5 points has been 
discussed to define MCI [10, 12], yet only very few studies 
have examined cut-off values for PD-MCI. A recent paper 
examining both Alzheimer’s disease and PD patients found 
that an FAQ score ≥ 3 was able to differentiate cognitively 
normal PD (PD-CN) and PD-MCI patients, after matching 
for age, sex, and education [13]. They found a low sen-
sitivity (38.1%) but high specificity (92.9%), attributing 
this to the fact that only a subgroup of PD-MCI patients 
presented with ADL dysfunction. A notable limitation 
of this study was that they did not examine the cognitive 
profile of PD patients stratified according to this cut-off. 
Standardized ADL assessments accompanied by neuropsy-
chological testing can further the understanding of how 
cognitive abilities are related to ADL impairment [14], 
which is necessary to identify measures that are sensitive 
to early changes in functional abilities.
The FAQ is most commonly completed by an informant, 
as statements by relatives about the patient ‘s ADL situa-
tion are often of great importance for further clinical deci-
sions. It can also be completed by the patient themselves if 
no caregiver is available, to provide insight into how cog-
nitive impairment affects their daily life. Previous research 
has shown that PD patients tend to underestimate their 
ADL impairment compared to their caregivers [14, 15]. 
However, not all studies have found differences between 
informant and self-reporting of ADL function in PD [16, 
17]. It is still unclear whether self-reports or informant 
reports are more useful in the clinical routine for judging 
cognitive-driven ADL deficits, as the discrepancy between 
the two types of reports have not been extensively studied.
The aim of this study was to examine the diagnostic 
abilities of different cut-off scores of the FAQ for differen-
tiating between levels of severity of cognitive impairment 
in PD, differentiating between informant and self-reports. 
For this purpose, diagnostic values of cut-offs reported in 
the literature and the optimal cut-off derived from the cur-
rent data were examined in an international pooled cohort 
of patients. Global cognitive function was also compared 
between groups for each cut-off, to determine how cognition 
relates to daily functioning in PD.
Methods
Study design and participants
Data of 679 patients were harmonized and analyzed within 
the frame of the CENTRE-PD project. Patients were 
recruited from the ABC-PD Study at the University Hospi-
tal in Tübingen (n = 226) [8], the Luxembourg Parkinson’s 
Study at the University of Luxembourg (n = 274) [18], and 
the OPDC Discovery Cohort at the University of Oxford 
(n = 179) [19]. All studies received ethical approval from 
local ethics committees; all patients gave written informed 
consent for respective study participation at each of the three 
study centers. For all studies, procedures were in accordance 
with the 1964 Helsinki declaration and its later amendments 
or comparable ethical standards.
Inclusion criteria for the analyses were age between 45 
and 90 years, and ability to give informed consent. Patients 
who met the following criteria were excluded: severe cog-
nitive impairment determined by a Montreal Cognitive 
Assessment (MoCA) score < 18 points (n = 14, 2.1%), major 
depression defined by a Beck Depression Inventory (BDI)-
II score > 19 points after conversion (44, 6.5%,), or missing 
demographic, FAQ, or MoCA data (32, 4.7%). Data of 589 
patients was included in the final data set.
Assessments
Demographics were collected for each patient, and the Uni-
fied Parkinson’s Disease Rating Scale-Part III (UPDRS-III) 
and the Hoehn and Yahr staging scale assessed motor sever-
ity [20]. Depressive symptomatology was assessed using the 
BDI versions I (BDI-I) [21] and II (BDI-II). All BDI-I values 
were converted to the appropriate BDI-II scores according 
to the BDI-II manual. The MoCA was used to assess global 
cognitive functioning [22]. According to Level-I criteria of 
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the Movement Disorders Society [23], patients were classi-
fied as PD-CN if they had an MoCA score ≥ 26, or as PD-
MCI if they scored between 18 and 25 points. The FAQ, 
which consists of ten items, each rated from 0 (normal) to 3 
(dependent), was used to assess ADL impairment. The total 
score ranges from 0 to 30 points, with higher scores suggest-
ing greater functional dependence.
Statistical analyses
SPSS version 26 (SPSS Inc., Chicago, IL, USA) was used 
to conduct statistical analyses, with α levels set at 0.05. The 
Shapiro–Wilk test was applied to test for normal distribu-
tion of variables. Demographics were compared between 
cognitive groups (PD-CN and PD-MCI) using Chi-squared 
and Mann–Whitney-U tests where appropriate. A receiver 
operating characteristic (ROC) analysis was conducted to 
define the optimal (highest Youden’s Index) FAQ cut-off to 
define PD-MCI. The FAQ cut-offs chosen for the following 
analyses were (i) optimal cut-off identified from the ROC 
curve analysis, (ii) cut-off ≥ 3 shown to differentiate between 
PD-CN and PD-MCI [13], and (iii) a cut-off for MCI (≥ 5) 
in the general population [10, 12]. Sensitivity and specific-
ity as well as the positive predictive value (PPV) and nega-
tive predictive value (NPV) were calculated for each of the 
three cuts-offs. This was done separately for informant-rated 
FAQ and self-rated FAQ to compare the diagnostic abilities 
of both ratings. Binary logistic regressions examining the 
effect of the MoCA total score between each FAQ cut-off 
group while correcting for significant demographic variables 
were conducted in the informant-rated and self-rated FAQ 
groups separately. As the FAQ has been found to be depend-
ent on age in older adults [24], we chose to include age as a 
constant covariate, even if it was not significantly different 
between groups. It is also important to note that PD is a 
neurodegenerative disease, and increasing ADL and cogni-
tive impairment has been shown to be associated with motor 
symptom worsening and higher PD severity [25]. There-
fore, disease duration was also included as a covariate in 
all models.
Results
Of all patients, 225 (38.2%) were classified as PD-MCI 
and 364 (61.8%) as PD-CN. PD-MCI patients were signifi-
cantly older, had less formal education, had greater sever-
ity of motor symptoms, and showed more impairment with 
ADL activities than PD-CN (see Table 1). The FAQ was 
most commonly completed by the patient’s spouse (419, 
71.1%), followed by the patient themselves (136, 23.1%), 
the patient’s child (22, 3.7%), a close friend (7, 1.2%), or a 
non-specified informant (5, 0.8%).
The ROC curve analysis of the FAQ total score for diag-
nosing PD-MCI produced an area under the curve of 0.61 
and standard error 0.02, p < 0.001 (95% confidence interval: 
0.56–0.66), which was judged to be sufficient [26]. Diag-
nostic values for differentiating PD-CN from PD-MCI can 
be found in Table 2 for all three cut-offs. In all patients, 
132 (58.7%) of PD-MCI compared to 156 (42.9%) PD-CN 
Table 1  Demographic and 
clinical characteristics of the 
pooled sample
Results are expressed as median (range) except where noted; boldface indicates statistically significant val-
ues
BDI-II Beck Depression Inventory-II; FAQ Functional Activities Questionnaire; MoCA Montreal Cognitive 
Assessment; PD-CN Parkinson’s Disease with normal cognition; PD-MCI Parkinson’s disease with mild 
cognitive impairment; UPDRS-III Unified Parkinson’s Disease Rating Scale-Part III








Male sex: n (%) 388 (65.9) 224 (61.5) 164 (72.9) 0.006
Age (years) 68.47 (46.52–89.93) 65.29 (46.52–89.93) 72.30 (47.47–89.28)  < 0.001
Education years 13 (5–31) 14 (5–25) 12 (5–31)  < 0.001
Disease duration years 5 (0–31) 4.89 (0–26) 5.36 (0–31) 0.37
UPDRS-III total score 30 (1–81) 28 (1–79) 33 (3–81)  < 0.001
Hoehn and Yahr: n (%)  < 0.001
1 49 (8.3) 38 (10.4) 11 (4.9)
2 387 (65.7) 252 (69.3) 135 (60)
3 137 (23.3) 68 (18.7) 69 (30.7)
4 16 (2.7) 6 (1.6) 10 (4.4)
BDI-II total score 7 (0–19) 7 (0–19) 8 (0–19) 0.56
FAQ total score 0 (0–29) 0 (0–21) 2 (0–29)  < 0.001
MoCA total score 26 (18–30) 28 (26–30) 23 (18–25) –*
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patients scored ≥ 1 on the FAQ. Eighty-eight (39.1%) PD-
MCI compared to 78 (21.4%) PD-CN patients scored above 
the cut-off of 3. For FAQ ≥ 5, 57 (25.3%) PD-MCI compared 
to only 51 (14%) of PD-CN patients scored above the cut-off.
Informant analyses
Demographics for groups split according to each of the 
three cut-offs are shown in Supplementary Table 1. For 
all cut-offs, significant differences were found for age, dis-
ease duration, UPDRS-III, BDI-II, and MoCA total scores, 
where patients scoring above each cut-off were older, had 
more severe motor impairment and longer disease durations, 
increased depressive symptomatology, and lowered cogni-
tion. There was a significant effect of sex for the cut-off 
of 1, with more males scoring above the cut-off. Addition-
ally, patients scoring above the cut-off of 5 had significantly 
lower formal education years than those scoring below the 
cut-off. Diagnostic ability for differentiating PD-CN from 
PD-MCI for all three cut-off values can be found in Table 2.
Binary logistic regressions were used to examine the 
effect of the MoCA, age, and significant demographic vari-
ables on each FAQ cut-off (see Table 3). When correcting 
for sex, age, disease duration, UPDRS-III, and BDI-II, 
the regression model for FAQ cut-off of 1 [χ2(6) = 86.23, 
p < 0.001] was not predicted by the MoCA. Splitting the 
groups according to the FAQ cut-off 3 [model: χ2(5) = 96.88, 
p < 0.001], with age, disease duration, UPDRS-III, and the 
BDI-II as covariates, also did not reveal a significant effect 
of the MoCA. For the FAQ cut-off of 5 using age, education, 
Table 2  Diagnostic values of the FAQ total score for differentiating 
between PD-CN and PD-MCI according to each chosen cut-off value
FAQ Functional Activities Questionnaire; NPV negative predictive 
value; PPV positive predictive value
FAQ cut-off Sensitivity Specificity PPV NPV
All patients
  ≤ 1 0.59 0.57 0.46 0.69
  ≤ 3 0.39 0.79 0.53 0.68
  ≤ 5 0.25 0.86 0.53 0.65
Informant ratings
  ≤ 1 0.54 0.67 0.52 0.69
  ≤ 3 0.32 0.90 0.68 0.68
  ≤ 5 0.22 0.95 0.75 0.65
Self ratings
  ≤ 1 0.60 0.54 0.44 0.69
  ≤ 3 0.42 0.75 0.50 0.68
  ≤ 5 0.26 0.83 0.49 0.65
Table 3  Binary logistic 
regression models between 
Functional Activities 
Questionnaire Cut-offs and the 
Montreal Cognitive Assessment 
for Informant Ratings
Boldface indicates statistically significant values
B unstandardized beta; BDI-II Beck Depression Inventory-II; CI confidence interval of the odds ratio; 
MoCA Montreal Cognitive Assessment; SE B standard error for unstandardized beta; UPDRS-III, Unified 
Parkinson’s Disease Rating Scale III
Model Predictors Nagelkerke R2 B SE B p-value Odds ratio 95% CI
(lower–upper)
Cut-off 1 0.23
MoCA total score  − 0.02 0.04 0.64 0.98 0.91–1.06
Sex  − 0.51 0.23 0.02 0.60 0.39–0.93
Age 0.02 0.01 0.06 1.02 1.00–1.05
Disease duration 0.02 0.03 0.40 1.02 0.97–1.07
UPDRS-III 0.04 0.01  < 0.001 1.04 1.02–1.06
BDI-II 0.12 0.02  < 0.001 1.13 1.08–1.17
Cut-off 3 0.27
MoCA  − 0.05 0.04 0.22 0.95 0.87–1.03
Age 0.03 0.01 0.04 1.03 1.00–1.06
Disease duration 0.05 0.03 0.04 1.06 1.00–1.11
UPDRS-III 0.04 0.01  < 0.001 1.04 1.02–1.07
BDI-II 0.12 0.02  < 0.001 1.12 1.07–1.18
Cut-off 5 0.26
MoCA  − 0.01 0.05 0.84 0.99 0.90–1.09
Age 0.04 0.02 0.01 1.05 1.01–1.08
Education years  − 0.06 0.04 0.10 0.94 0.87–1.01
Disease duration 0.03 0.03 0.36 1.03 0.97–1.09
UPDRS-III 0.05 0.01  < 0.001 1.05 1.03–107
BDI-II 0.11 0.03  < 0.001 1.12 1.06–1.17
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disease duration, UPDRS-III, and the BDI-II as covariates 
[model fit: χ2(6) = 82.31, p < 0.001], the MoCA did not sig-
nificantly differentiate between groups.
Self‑report analyses
Supplementary Table 2 shows the demographics for all three 
groups split according to the cut-offs. Significant effects 
were found for all three cut-offs for UPDRS-III and MoCA 
total scores, with patients scoring below each cut-off show-
ing increased motor severity and lowered cognition. There 
was a significant effect of the BDI-II for cut-offs 3 and 5, 
with patients scoring above the cut-off displaying greater 
depressive symptoms than those below the cut-offs. Addi-
tionally, an effect of disease duration was found for the cut-
off of 3, where patients scoring above the cut-off had longer 
disease durations than those below the cut-off. Table 2 shows 
the diagnostic values for differentiating PD-CN from PD-
MCI for all three cut-offs.
Relation between FAQ groups per cut-off and the MoCA, 
including age and significant demographic variables as 
covariates, was examined using binary logistic regressions 
(see Table 4). The model using the FAQ cut-off of 1 and 
age, disease duration, UPDRS-III, and BDI-II as covari-
ates was stable, χ2(4) = 15.97, p = 0.007, yet the MoCA 
was not able to differentiate between groups. Splitting the 
groups according to the FAQ cut-off 3 [model: χ2(5) = 35.49, 
p < 0.001] using age, disease duration, UPDRS-III, and 
the BDI-II as covariates showed a significant effect of 
the MoCA [B =  − 0.31, Exp(B) = 0.74, p = 0.003], where 
patients with an FAQ ≥ 3 had worse cognition. For the FAQ 
cut-off of 5 and correcting for age and UPDRS-III [model 
fit: χ2(3) = 20.74, p < 0.001], the MoCA showed moderate 
evidence for differentiating between groups, although this 
did not reach significance.
Discussion
Recent studies have shown that PD-MCI patients already 
show the first signs of ADL dysfunctions [6, 9]; however, 
the quantification of these deficits remains difficult. The aim 
of this study was to examine the diagnostic abilities of dif-
ferent cut-off scores of the FAQ (from the current data set 
as well as the literature) for differentiating not only between 
cognitive impairment levels but also between informant and 
self-reports of ADL abilities.
The current results demonstrate that with increasingly 
higher FAQ cut-offs, for both self and informant reports, 
specificity increases indicating a higher ability of the cut-off 
to correctly identify PD-CN patients without ADL impair-
ment. However, sensitivity also decreases, leading to a 
decrease in true positive patients among the PD-MCI group. 
In the original study [10], the FAQ presented good sensitiv-
ity (0.85) and specificity (0.81) in terms of distinguishing 
normal healthy individuals and those with cognitive decline. 
Table 4  Binary logistic 
regression models between 
Functional Activities 
Questionnaire Cut-offs and the 
Montreal Cognitive Assessment 
for Self Ratings
Boldface indicates statistically significant values
B unstandardized beta; BDI-II Beck Depression Inventory-II; CI confidence interval of the odds ratio; 
MoCA Montreal Cognitive Assessment; SE B standard error for unstandardized beta; UPDRS-III Unified 
Parkinson’s Disease Rating Scale III
Model Predictors Nagelkerke R2 B SE B p-value Odds ratio 95% CI
(lower–upper)
Cut-off 1 0.15
MoCA total score  − 0.08 0.07 0.25 0.92 0.80–1.06
Age 0.02 0.02 0.40 1.02 0.97–1.07
Disease duration 0.03 0.05 0.55 1.03 0.93–1.15
UPDRS-III 0.04 0.02 0.02 1.04 1.01–1.07
BDI-II 0.04 0.04 0.31 1.04 0.96–1.13
Cut-off 3 0.37
MoCA  − 0.31 0.10 0.003 0.74 0.60–0.90
Age  − 0.01 0.04 0.80 0.99 0.92–1.06
Disease duration 0.09 0.08 0.27 1.09 0.94–1.27
UPDRS-III 0.06 0.02 0.01 1.06 1.02–1.11
BDI-II 0.12 0.06 0.03 1.13 1.01–1.26
Cut-off 5 0.28
MoCA  − 0.21 0.11 0.06 0.81 0.65–1.01
Age 0.05 0.04 0.26 1.05 0.97–1.13
Disease duration 0.06 0.08 0.49 1.06 0.90–1.24
UPDRS-III 0.06 0.02 0.01 1.07 1.02–1.12
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In our international PD sample, we were able to replicate 
the specificity in both analyses for the cut-offs 3 and 5, yet 
the sensitivity was lacking for all (< 0.45). This finding of a 
low sensitivity of the FAQ compared to the higher specifity 
for ADL impairment in PD-MCI is similar to a recent study 
which found sensitivity and specificity (38.1% and 92.9%, 
respectively) using the FAQ cut-off ≥ 3 [13]. One reason for 
this effect could be that ADL impairment arises in the more 
advanced disease stage of PD-MCI and is limited to only a 
subgroup of PD-MCI patients. Mild ADL impairment pri-
marily related to loss of cognitive function has been detected 
in ~ 30% of PD-MCI with various measurements [8, 9], sup-
porting our hypothesis.
It should also be noted that assessing ADL impairments 
is difficult in PD, as motor impairments interfere with daily 
functioning [27]. The progression of motor dysfunction in 
PD, coupled with increasing age, leads to a poorer ability to 
execute ADL [28, 29] and a reduced health-related quality 
of life [30], while cognition and ADL function may decline 
in parallel [31, 32]. This may suggest that ADL functions 
simply decline with progression of the disease. However, 
a recent study examined both motor and cognitive influ-
ences on the FAQ in non-demented PD patients [8]. Results 
showed that PD-MCI patients had more cognitive-driven 
and motor-driven ADL impairments than PD-CN patients. 
As disease duration was not significant between the groups, 
it can be said that ADL impairments are more severe in PD-
MCI patients irrespective of disease course. Future studies 
are needed to evaluate the predicitive value of mild ADL 
impairment in prodomal stage of PDD with the intention 
of further characterizing a high-risk group for conversion 
to dementia in PD and comparing between different types 
of PD-MCI.
We also investigated associations between the different 
FAQ cut-offs and the MoCA, a measure of global cognition. 
These associations were assessed separately for the FAQ 
rated by informants and the FAQ rated by the patient them-
selves. The accuracy of both patient and informant percep-
tions of ADL impairment, especially in the prodromal stage 
of PDD, has been sparsely studied. For the informant ratings, 
no FAQ cut-off was significantly associated with the MoCA 
after adjustment for other covariates. However, the cut-off 
of 3 in the self-report analyses was able to show a significant 
association with the MoCA, and the cut-off of 5 showed 
moderate evidence of an association which did not reach 
clinical significance. It should be noted that fewer patients 
scored above the cut-off of 5 than the cut-off of 3, which 
limits the statistical power in our sample. Our results are 
strengthened by other studies that have shown that patients 
can assess their own neuropsychological performance more 
accurately [33]. However, previous studies have found that 
informant reports are related to objective neuropsychological 
performance and more accurate than self-reports [17]. We 
could not replicate this by using the MoCA score as an exter-
nal criteria to verify that the classified mild ADL impair-
ment is related to cognitive dysfunction. Caregiver burden, 
including stress and depression, has been shown to affect 
informants’ ratings of functional abilities [34, 35]. As these 
were not measured in our study, it is possible that their influ-
ence on informant evaluations led to the null effects found 
in the current results. Moreover, informants might have the 
tendency to overestimate motor impairment on ADL per-
formance [15], which could explain the lack of a significant 
effect on the MoCA score after diving the sample according 
to type of FAQ informant. Our current data indicate that 
self-reported ADL impairment assessed by the FAQ showed 
a relation to the severity of cognitive impairment in PD.
It is possible that ADL scales can serve as screening tools 
for clinicians to decide which further assessments, such as 
neuropsychological tests, are necessary [14]. The main 
advantage of the FAQ is that it is a short and easy to apply 
measure and could be administered quickly at patient visits 
by doctors to gauge functional abilities. However, due to 
the low specificities found for the different cut-offs used, 
it seems that the FAQ may not be useful as a stand-alone 
assessment for detecting cognitive impairment and may not 
offer a significant advantage compared to cognitive tests. 
We would argue that until a definitive cut-off value with 
adequate sensitivity and specificity can be identified for each 
cognitive group, the FAQ should be used in conjunction with 
neuropsychological tests, in line with the current recom-
mendation of the Movement Disorders Society [23]. Per-
haps the FAQ is more useful in detecting subtle changes in 
ADL function over time, even in different cognitive groups, 
which would make it an extremely valuable tool for track-
ing progression. Compared to healthy controls, PD patients 
are four times more likely to lose functional independence 
[36]. As this loss is irreversible, future studies should aim 
to improve the cut-off of the FAQ for identifying patients at 
risk of rapid decline in ADL function.
Limitations
Some limitations need to be taken into account. The data 
analyzed were collected from different countries, raising 
the possibility of cross-cultural differences affecting the 
results; however, a previous study showed that the FAQ 
performed well across different ethnic groups [37]. As cog-
nition is negatively influenced by severe depression [38], 
we excluded patients who showed signs of major depres-
sion which limits the generalization of our results to the 
larger population. Furthermore, to diagnose PD-MCI, only 
Level-I classification was used, instead of a comprehensive 
neuropsychological battery (Level-II), which may have led 




This study has taken an important step towards determin-
ing a suitable cut-off for ADL dysfunctions in PD-MCI. Our 
data argue that the presence of mild ADL impairment in PD 
is associated with cognitive impairment. The utility of the 
FAQ for diagnosing PD-MCI may therefore be difficult due 
to the lack of specific criteria defining ADL impariment in 
PD-MCI. Future studies are needed to verify whether these 
patients are at greater risk for PDD conversion. If ADL func-
tion declines early in the disease course, and possibly reflects 
faster cognitive decline, it would be paramount to identify 
when to start treatments and to further research into examin-
ing what treatments can be developed.
Supplementary Information The online version contains supplementary 
material available at https:// doi. org/ 10. 1007/ s10072- 021- 05365-1.
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